Tags > Medication Updates
Year: Medication: Abilify (aripiprazole) Addyi Antipsychotics Aripiprazole Aristada Belsomra Brintellix Buprenorphine and naloxone Probuphine Clozapine Chantix and Zyban Cymbalta Daytrana Diazepam Effexor Farxiga Fentanyl and Opioids Geodon Hysingla ER Ingrezza Lamictal (lamotrigine) Lorazepam Lucemyra (lofexidine hydrochloride) Lunesta Methylphenidate Naloxone/Evzio Naltrexone Olanzapine Olanzapine/Zyprexa Opana ER Opioids Opioids and Benzodiazepines UPDATE: Opioids and Benzodiazepines Rexulti Strattera Sublocade Tanzeum Targiniq ER Tramadol Treatment for Alcohol Use Disorder Vraylar Vynase Ziprasidone Zolpidem Zyprexa General Resources: DEA Pharmacists' Manual FDA Medication Updates NIMH Mental Health Medications Guide 2018 FDA warns about immune system reaction with Lamictal (lamotrigine) This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly. FDA approves Lucemyra for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. Drug may lessen the severity of withdrawal symptoms, but may not completely prevent them and is only approved for treatment for up to 14 days.
View all tags